NCT03834376No Longer Available不适用
Pimodivir (JNJ-63623872) Pre Approval Access_Single Patient Access (SPR) for Patients Diagnosed With H7N9 Influenza A Infection
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
The purpose of this program is to provide pre-approval access to pimodivir for the treatment of a patient(s) with H7N9 influenza A infection. Pre-approval access pertains to provision for therapeutic use of an investigational product prior to its marketing authorization. Such access may be considered for eligible patients with serious/life-threatening diseases or conditions, where alternative treatments do not exist or have been exhausted.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has an H7N9 Influenza A infection
- •The patient has no known severe hepatic impairment
排除标准
- •Any other Influenza A sub-strains other than H7N9
研究者
相似试验
No Longer Available
不适用
Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric ParticipantsRespiratory Syncytial VirusNCT04221412Janssen Sciences Ireland UC
Unknown
不适用
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05503550Janssen Research & Development, LLC
Approved For Marketing
不适用
Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 InfectionHIVNCT03847376Janssen Sciences Ireland UC
Approved For Marketing
不适用
Expanded Access of Pimavanserin for Patients With PD PsychosisParkinson's Disease PsychosisNCT02762591ACADIA Pharmaceuticals Inc.
Approved For Marketing
不适用
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNCT04599712Janssen Research & Development, LLC